Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)
China flag China · Delayed Price · Currency is CNY
18.46
+1.68 (10.01%)
Jun 20, 2025, 2:45 PM CST

SHA:603538 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
4,0582,7804,0805,4945,3125,555
Upgrade
Market Cap Growth
4.44%-31.86%-25.74%3.44%-4.38%50.31%
Upgrade
Enterprise Value
4,8563,5034,6206,1815,9345,985
Upgrade
Last Close Price
18.4612.7119.0925.5025.0626.20
Upgrade
PE Ratio
54.4941.62352.1916.2237.2735.62
Upgrade
Forward PE
24.2913.3123.4618.9024.7023.60
Upgrade
PS Ratio
2.932.033.353.774.224.66
Upgrade
PB Ratio
1.751.211.872.532.693.13
Upgrade
P/TBV Ratio
2.011.402.112.833.434.14
Upgrade
P/OCF Ratio
32.0828.51446.7619.8424.0824.36
Upgrade
EV/Sales Ratio
3.502.553.804.244.725.02
Upgrade
EV/EBITDA Ratio
20.8315.6833.0120.3522.0724.91
Upgrade
EV/EBIT Ratio
50.5437.33175.2430.0934.9239.18
Upgrade
Debt / Equity Ratio
0.590.590.600.550.640.45
Upgrade
Debt / EBITDA Ratio
5.915.918.993.924.693.33
Upgrade
Asset Turnover
0.310.300.280.350.350.42
Upgrade
Inventory Turnover
1.251.371.451.521.531.85
Upgrade
Quick Ratio
0.580.710.800.900.900.56
Upgrade
Current Ratio
1.211.241.281.391.481.03
Upgrade
Return on Equity (ROE)
3.69%3.40%0.74%17.71%8.42%9.67%
Upgrade
Return on Assets (ROA)
1.34%1.29%0.37%3.05%2.98%3.33%
Upgrade
Return on Capital (ROIC)
1.67%1.65%0.48%3.88%3.65%4.03%
Upgrade
Return on Capital Employed (ROCE)
3.20%3.10%0.90%6.70%6.00%7.80%
Upgrade
Earnings Yield
1.82%2.40%0.28%6.17%2.68%2.81%
Upgrade
FCF Yield
-0.40%-2.94%-5.16%-5.36%-5.82%-1.59%
Upgrade
Dividend Yield
0.30%0.39%0.10%0.65%0.57%-
Upgrade
Payout Ratio
32.75%34.00%511.34%14.76%9.71%26.61%
Upgrade
Buyback Yield / Dilution
5.10%6.99%-1.89%-6.91%-3.50%-0.07%
Upgrade
Total Shareholder Return
5.39%7.39%-1.78%-6.26%-2.93%-0.07%
Upgrade
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.